Other Species / Isoforms
  LATS1 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
T17-p
YRQMRPKtFPASNyT
0 13
LATS1 (human) YRQMRPKtFPASNyT T17-p
LATS1 (mouse) YRQMRPKTFPASNYP T17
LATS1 (rat) YRQMRPKTFPASNYS T17
Y23-p
KtFPASNyTVssRQM
0 1
LATS1 (human) KtFPASNyTVssRQM Y23-p
LATS1 (mouse) KTFPASNYPGSSRQM Y23
LATS1 (rat) KTFPASNYSGSSRQM Y23
S26-p
PASNyTVssRQMLQE
0 2
LATS1 (human) PASNyTVssRQMLQE S26-p
LATS1 (mouse) PASNYPGSSRQMLQE S26
LATS1 (rat) PASNYSGSSRQMLQE S26
S27-p
ASNyTVssRQMLQEI
0 1
LATS1 (human) ASNyTVssRQMLQEI S27-p
LATS1 (mouse) ASNYPGSSRQMLQEI S27
LATS1 (rat) ASNYSGSSRQMLQEI S27
S37-p
MLQEIREsLRNLsKP
0 2
LATS1 (human) MLQEIREsLRNLsKP S37-p
LATS1 (mouse) MLQEIREsLRNLSKP S37-p
LATS1 (rat) MLQEIRESLRNLSKP S37
S42-p
REsLRNLsKPSDAAK
Upstream
0 1
Treatment
  • BI2536
LATS1 (human) REsLRNLsKPSDAAK S42-p
LATS1 (mouse) REsLRNLSKPSDASK S42
LATS1 (rat) RESLRNLSKPSDAAK S42
K76-ub
PKFGTHHkALQEIRN
0 1
LATS1 (human) PKFGTHHkALQEIRN K76-ub
LATS1 (mouse) PKFGTHHKALQEIRN K76
LATS1 (rat) PKFGTHHKALQEIRN K76
S84-p
ALQEIRNsLLPFANE
0 3
LATS1 (human) ALQEIRNsLLPFANE S84-p
LATS1 (mouse) ALQEIRNSLLPFANE S84
LATS1 (rat) ALQEIRNSLLPFANE S84
N93
LPFANETNSSRSTSE
0 1
LATS1 (human) LPFANETNSSRSTSE N93
LATS1 (mouse) LPFANETsSSRSPSE S93-p
LATS1 (rat) LPFANETSSSRIPSE S93
Y143-p
EFISKMSyQDPRREQ
0 1
LATS1 (human) EFISKMSyQDPRREQ Y143-p
LATS1 (mouse) EFISKMSYQDPRREQ Y143
LATS1 (rat) EFISKMSYQDPRREQ Y143
S171-p
KPGNVQQsVNRKQsW
0 1
LATS1 (human) KPGNVQQsVNRKQsW S171-p
LATS1 (mouse) KPGNVQHSINRKQsW S171
LATS1 (rat) KPGNVQHSISRKQSW S171
S177-p
QsVNRKQsWKGsKES
Upstream
0 6
Treatment
  • ischemia
LATS1 (human) QsVNRKQsWKGsKES S177-p
LATS1 (mouse) HSINRKQsWKGsKES S177-p
LATS1 (rat) HSISRKQSWKGSKES S177
S181-p
RKQsWKGsKESLVPQ
0 8
LATS1 (human) RKQsWKGsKESLVPQ S181-p
LATS1 (mouse) RKQsWKGsKESLVPQ S181-p
LATS1 (rat) RKQSWKGSKESLVPQ S181
Y200
PLGESVAYHSESPNS
1 1
LATS1 (human) PLGESVAYHSESPNS Y200
LATS1 (mouse) SLGENVVyRSEsPNs Y200-p
LATS1 (rat) SLGENVVYRSESPNS Y200
S204
SVAYHSESPNSQTDV
0 2
LATS1 (human) SVAYHSESPNSQTDV S204
LATS1 (mouse) NVVyRSEsPNsQADV S204-p
LATS1 (rat) NVVYRSESPNSQADV S204
S207
YHSESPNSQTDVGRP
0 1
LATS1 (human) YHSESPNSQTDVGRP S207
LATS1 (mouse) yRSEsPNsQADVGRP S207-p
LATS1 (rat) YRSESPNSQADVGRP S207
S216
TDVGRPLSGSGISAF
0 1
LATS1 (human) TDVGRPLSGSGISAF S216
LATS1 (mouse) ADVGRPLsGsGIAAF S216-p
LATS1 (rat) ADVGRPLSGSGITAF S216
S218
VGRPLSGSGISAFVQ
0 1
LATS1 (human) VGRPLSGSGISAFVQ S218
LATS1 (mouse) VGRPLsGsGIAAFAQ S218-p
LATS1 (rat) VGRPLSGSGITAFAQ S218
R243-m1
PPPPPQVrsVtPPPP
0 1
LATS1 (human) PPPPPQVrsVtPPPP R243-m1
LATS1 (mouse) PPPPPQVRSVtPPPP R243
LATS1 (rat) PPPPPQVRSVtPPPP R243
S244-p
PPPPQVrsVtPPPPP
0 2
LATS1 (human) PPPPQVrsVtPPPPP S244-p
LATS1 (mouse) PPPPQVRSVtPPPPP S244
LATS1 (rat) PPPPQVRSVtPPPPP S244
T246-p
PPQVrsVtPPPPPrG
Upstream
0 35
Treatment
  • MG132_withdrawal
LATS1 (human) PPQVrsVtPPPPPrG T246-p
LATS1 (mouse) PPQVRSVtPPPPPRG T246-p
LATS1 (rat) PPQVRSVtPPPPPRG T246-p
R252-m1
VtPPPPPrGQtPPPr
0 1
LATS1 (human) VtPPPPPrGQtPPPr R252-m1
LATS1 (mouse) VtPPPPPRGQtPPPR R252
LATS1 (rat) VtPPPPPRGQTPPPR R252
T255-p
PPPPrGQtPPPrGtt
0 12
LATS1 (human) PPPPrGQtPPPrGtt T255-p
LATS1 (mouse) PPPPRGQtPPPRGTT T255-p
LATS1 (rat) PPPPRGQTPPPRGTT T255
R259-m1
rGQtPPPrGttPPPP
0 2
LATS1 (human) rGQtPPPrGttPPPP R259-m1
LATS1 (mouse) RGQtPPPRGTTPPPP R259
LATS1 (rat) RGQTPPPRGTTPPPP R259
T261-p
QtPPPrGttPPPPSW
0 1
LATS1 (human) QtPPPrGttPPPPSW T261-p
LATS1 (mouse) QtPPPRGTTPPPPSW T261
LATS1 (rat) QTPPPRGTTPPPPSW T261
T262-p
tPPPrGttPPPPSWE
0 1
LATS1 (human) tPPPrGttPPPPSWE T262-p
LATS1 (mouse) tPPPRGTTPPPPSWE T262
LATS1 (rat) TPPPRGTTPPPPSWE T262
K275-m1
WEPNSQTkRysGNME
0 1
LATS1 (human) WEPNSQTkRysGNME K275-m1
LATS1 (mouse) WEPSSQTKRysGNME K275
LATS1 (rat) WEPNSQTKRYSGNME K275
Y277-p
PNSQTkRysGNMEyV
1 3
LATS1 (human) PNSQTkRysGNMEyV Y277-p
LATS1 (mouse) PSSQTKRysGNMEYV Y277-p
LATS1 (rat) PNSQTKRYSGNMEYV Y277
S278-p
NSQTkRysGNMEyVI
0 25
LATS1 (human) NSQTkRysGNMEyVI S278-p
LATS1 (mouse) SSQTKRysGNMEYVI S278-p
LATS1 (rat) NSQTKRYSGNMEYVI S278
Y283-p
RysGNMEyVISRISP
Upstream
0 51
Treatment
  • ephrin_B1
LATS1 (human) RysGNMEyVISRISP Y283-p
LATS1 (mouse) RysGNMEYVISRISP Y283
LATS1 (rat) RYSGNMEYVISRISP Y283
S336-p
PIIMQSSsKFNFPSG
0 2
LATS1 (human) PIIMQSSsKFNFPSG S336-p
LATS1 (mouse) PIIMQSTSKFNFTPG S336
LATS1 (rat) PIIMQSTSKFNFTPG S336
S462-p
QPNIPVRsNsFNNPL
0 6
LATS1 (human) QPNIPVRsNsFNNPL S462-p
LATS1 (mouse) QPNIPVRSNsFNNPL S461
LATS1 (rat) QPNIPVRsNsFNNPL S462-p
S464-p
NIPVRsNsFNNPLGN
Upstream
Downstream
1 58
Effects on Modified Protein
  • protein degradation
Kinase, in vitro:
  • NuaK1 (human)
  • NuaK2 (human)
Putative in vivo kinases:
  • NuaK1 (human)
Treatment
  • angiotensin_2
  • AZD1152
  • BI2536
  • MG132_withdrawal
  • ZM447439
LATS1 (human) NIPVRsNsFNNPLGN S464-p
LATS1 (mouse) NIPVRSNsFNNPLGS S463-p
LATS1 (rat) NIPVRsNsFNNPLGS S464-p
T490-p
ATTVTAItPAPIQQP
Upstream
1 0
Kinase, in vitro:
  • CDK1 (human)
LATS1 (human) ATTVTAItPAPIQQP T490-p
LATS1 (mouse) ATTVTAITPAPIQQP T489
LATS1 (rat) ATTVTAITPAPIQQP T490
S580-p
YESISKPsKEDQPSL
0 1
LATS1 (human) YESISKPsKEDQPSL S580-p
LATS1 (mouse) YESVSKPCKDEQPSL C579
LATS1 (rat) YESASKPCKDDQPSS C580
S596-p
KEDESEKsYENVDSG
0 1
LATS1 (human) KEDESEKsYENVDSG S596-p
LATS1 (mouse) KEDDSEKSADSGDSG S595
LATS1 (rat) KEEDSEKSLDSVDSG S596
T611
DKEKKQITtsPItVR
0 2
LATS1 (human) DKEKKQITtsPItVR T611
LATS1 (mouse) DKEKKQIttsPITVR T610-p
LATS1 (rat) DKEKKQITTsPITVR T611
T612-p
KEKKQITtsPItVRK
0 4
LATS1 (human) KEKKQITtsPItVRK T612-p
LATS1 (mouse) KEKKQIttsPITVRK T611-p
LATS1 (rat) KEKKQITTsPITVRK T612
S613-p
EKKQITtsPItVRKN
Upstream
1 25
Kinase, in vitro:
  • CDK1 (human)
Putative in vivo kinases:
  • CDK1 (human)
Treatment
  • MG132_withdrawal
  • nocodazole
LATS1 (human) EKKQITtsPItVRKN S613-p
LATS1 (mouse) EKKQIttsPITVRKN S612-p
LATS1 (rat) EKKQITTsPITVRKN S613-p
T616-p
QITtsPItVRKNKKD
0 2
LATS1 (human) QITtsPItVRKNKKD T616-p
LATS1 (mouse) QIttsPITVRKNKKD T615
LATS1 (rat) QITTsPITVRKNKKD T616
S633-p
RRESRIQsYsPQAFK
0 1
LATS1 (human) RRESRIQsYsPQAFK S633-p
LATS1 (mouse) RRESRIQSYSPQAFK S632
LATS1 (rat) RRESRIQSYSPQAFK S633
S635-p
ESRIQsYsPQAFKFF
0 1
LATS1 (human) ESRIQsYsPQAFKFF S635-p
LATS1 (mouse) ESRIQSYSPQAFKFF S634
LATS1 (rat) ESRIQSYSPQAFKFF S635
K662-ub
QQRLHRKkQLENEMM
0 1
LATS1 (human) QQRLHRKkQLENEMM K662-ub
LATS1 (mouse) QQRLHRKKQLENEMM K661
LATS1 (rat) QQRLHRKKQLENEMM K662
S674-p
EMMRVGLsQDAQDQM
Upstream
1 1
Kinase, in vitro:
  • LATS1 (human)
LATS1 (human) EMMRVGLsQDAQDQM S674-p
LATS1 (mouse) EMMRVGLSQDAQDQM S673
LATS1 (rat) EMMRVGLSQDAQDQM S674
K683
DAQDQMRKMLCQkES
0 2
LATS1 (human) DAQDQMRKMLCQkES K683
LATS1 (mouse) DAQDQMRkMLCQKES K682-ac
LATS1 (rat) DAQDQMRKMLCQKES K683
K688-ub
MRKMLCQkESNYIRL
0 3
LATS1 (human) MRKMLCQkESNYIRL K688-ub
LATS1 (mouse) MRkMLCQKESNYIRL K687
LATS1 (rat) MRKMLCQKESNYIRL K688
K728-ub
LARKVDTkALYATkt
0 1
LATS1 (human) LARKVDTkALYATkt K728-ub
LATS1 (mouse) LARKVDTKALYATKT K727
LATS1 (rat) LARKVDTKALYATKT K728
K734-ub
TkALYATktLRKKDV
0 1
LATS1 (human) TkALYATktLRKKDV K734-ub
LATS1 (mouse) TKALYATKTLRKKDV K733
LATS1 (rat) TKALYATKTLRKKDV K734
T735-p
kALYATktLRKKDVL
0 3
LATS1 (human) kALYATktLRKKDVL T735-p
LATS1 (mouse) KALYATKTLRKKDVL T734
LATS1 (rat) KALYATKTLRKKDVL T735
K751-sm
RNQVAHVkAERDILA
Upstream
Downstream
1 0
Effects on Modified Protein
  • enzymatic activity, inhibited
  • phosphorylation
Effects on Biological Processes:
  • apoptosis, inhibited
  • carcinogenesis, induced
  • cell growth, induced
  • signaling pathway regulation
Treatment
  • siRNA
LATS1 (human) RNQVAHVkAERDILA K751-sm
LATS1 (mouse) RNQVAHVKAERDILA K750
LATS1 (rat) RNQVAHVKAERDILA K751
S792-p
IPGGDMMsLLIRMGI
0 1
LATS1 (human) IPGGDMMsLLIRMGI S792-p
LATS1 (mouse) IPGGDMMSLLIRMGI S791
LATS1 (rat) IPGGDMMSLLIRMGI S792
K830-sm
GFIHRDIkPDNILID
Downstream
1 0
Effects on Modified Protein
  • enzymatic activity, induced
Effects on Biological Processes:
  • transcription, induced
LATS1 (human) GFIHRDIkPDNILID K830-sm
LATS1 (mouse) GFIHRDIKPDNILID K829
LATS1 (rat) GFIHRDIKPDNILID K830
K860-ub
FRWTHDSkYYQsGDH
Upstream
Downstream
1 0
Effects on Modified Protein
  • intracellular localization
  • protein degradation
Effects on Biological Processes:
  • carcinogenesis, induced
  • cell growth, induced
  • cell motility, induced
  • transcription, induced
Treatment
  • glucose_starvation
  • siRNA
LATS1 (human) FRWTHDSkYYQsGDH K860-ub
LATS1 (mouse) FRWTHDSKYYQSGDH K859
LATS1 (rat) FRWTHDSKYYQSGDH K860
S864-p
HDSkYYQsGDHPRQD
0 1
LATS1 (human) HDSkYYQsGDHPRQD S864-p
LATS1 (mouse) HDSKYYQSGDHPRQD S863
LATS1 (rat) HDSKYYQSGDHPRQD S864
S872-p
GDHPRQDsMDFSNEW
Upstream
Downstream
2 4
Effects on Modified Protein
  • intracellular localization
  • phosphorylation
  • protein degradation
Effects on Biological Processes:
  • carcinogenesis, inhibited
  • signaling pathway regulation
Kinase, in vitro:
  • MST2 (human)
Regulatory protein:
  • RAB11A (human)
LATS1 (human) GDHPRQDsMDFSNEW S872-p
LATS1 (mouse) GDHPRQDSMDFSNEW S871
LATS1 (rat) GDHPRQDSMDFSSEW S872
S909-p
HQRCLAHsLVGTPNY
Upstream
Downstream
26 19
LATS1 (human)
S909-p
LATS1 (mouse)
S908-p
LATS1 (rat)
S909-p
Effects on Modified Protein
  • enzymatic activity, induced
  • intracellular localization
  • phosphorylation
  • protein degradation
Effects on Biological Processes:
  • carcinogenesis, inhibited
  • cell growth, induced
  • signaling pathway regulation
  • transcription, inhibited
Kinase, in vitro:
  • LATS1 (human)
  • MST2 (human)
Regulatory protein:
  • COL4A1 (human)
  • FRK (human)
  • FRMD6 (human)
  • GRF-1 (human)
  • LATS1 (human)
  • RAB11A (human)
Treatment
  • 2-deoxyglucose
  • Ca(2+)
  • calmodulin
  • Cd(2+)
  • CNO
  • FGF2
  • glomerular antiserum
  • PD98059
  • phenformin
  • serum_starvation
  • U0126
  • virus infection
  • Y15
  • Zn(2+)
LATS1 (human) HQRCLAHsLVGTPNY S909-p
LATS1 (mouse) HQRCLAHsLVGTPNY S908-p
LATS1 (rat) HQRCLAHSLVGTPNY S909
T967-p
MKVINWQtSLHIPPQ
Upstream
1 0
Kinase, in vitro:
  • MST2 (human)
LATS1 (human) MKVINWQtSLHIPPQ T967-p
LATS1 (mouse) MKVINWQTSLHIPPQ T966
LATS1 (rat) MKVINWQTSLHIPPQ T967
K976-ub
LHIPPQAkLSPEAsD
0 1
LATS1 (human) LHIPPQAkLSPEAsD K976-ub
LATS1 (mouse) LHIPPQAKLSPEASD K975
LATS1 (rat) LHIPPQAKLSPEASD K976
S982-p
AkLSPEAsDLIIKLC
0 1
LATS1 (human) AkLSPEAsDLIIKLC S982-p
LATS1 (mouse) AKLSPEASDLIIKLC S981
LATS1 (rat) AKLSPEASDLIIKLC S982
K1005-ub
KNGADEIkAHPFFKt
0 2
LATS1 (human) KNGADEIkAHPFFKt K1005-ub
LATS1 (mouse) KNGADEIKAHPFFKT K1004
LATS1 (rat) KNGADEIKAHPFFKT K1005
T1012-p
kAHPFFKtIDFSSDL
Upstream
1 0
Kinase, in vitro:
  • MST2 (human)
LATS1 (human) kAHPFFKtIDFSSDL T1012-p
LATS1 (mouse) KAHPFFKTIDFSSDL T1011
LATS1 (rat) KAHPFFKTIDFSSDL T1012
K1029-ub
QSASYIPkITHPTDT
0 1
LATS1 (human) QSASYIPkITHPTDT K1029-ub
LATS1 (mouse) QSASYIPKITHPTDT K1028
LATS1 (rat) QSASYIPKITHPTDT K1029
K1046-ub
FDPVDPDkLWsDDNE
0 1
LATS1 (human) FDPVDPDkLWsDDNE K1046-ub
LATS1 (mouse) FDPVDPDKLWSDGSE K1045
LATS1 (rat) FDPVDPDKLWSDGNE K1046
S1049-p
VDPDkLWsDDNEEEN
Upstream
1 0
Kinase, in vitro:
  • LATS1 (human)
LATS1 (human) VDPDkLWsDDNEEEN S1049-p
LATS1 (mouse) VDPDKLWSDGSEEEN S1048
LATS1 (rat) VDPDKLWSDGNEEEN S1049
T1060-p
EEENVNDtLNGWYKN
Upstream
1 4
Kinase, in vitro:
  • MST2 (human)
LATS1 (human) EEENVNDtLNGWYKN T1060-p
LATS1 (mouse) EEENISDTLNGWYKN T1059
LATS1 (rat) EEENINDTLNGWYKN T1060
Y1076-p
KHPEHAFyEFtFRRF
0 10
LATS1 (human) KHPEHAFyEFtFRRF Y1076-p
LATS1 (mouse) KHPEHAFYEFtFRRF Y1075
LATS1 (rat) KHPEHAFYEFtFRRF Y1076
T1079-p
EHAFyEFtFRRFFDD
Upstream
Downstream
28 1
LATS1 (human)
T1079-p
LATS1 (mouse)
T1078-p
LATS1 (rat)
T1079-p
Effects on Modified Protein
  • activity, induced
  • enzymatic activity, induced
  • enzymatic activity, inhibited
  • intracellular localization
  • phosphorylation
  • protein degradation
Effects on Biological Processes:
  • carcinogenesis, inhibited
  • cell growth, inhibited
  • signaling pathway regulation
  • transcription, inhibited
Kinase, in vitro:
  • GCK (human)
  • HGK (human)
  • MINK (human)
  • MST1 (human)
  • MST2 (human)
  • TAO1 (human)
Putative in vivo kinases:
  • HGK (human)
Regulatory protein:
  • FAM40B (human)
  • FRK (human)
  • KIBRA (human)
  • LATS1 (human)
  • LKB1 (human)
  • MARK4 (human)
  • Merlin (human)
  • MST1 (human)
  • MST2 (human)
  • PPP2CA (human)
  • RAB11A (human)
  • SLMAP (human)
  • STRIP1 (human)
  • WWC2 (human)
  • WWC3 (human)
Treatment
  • 2-deoxyglucose
  • Ca(2+)
  • calmodulin
  • Cd(2+)
  • Clostridium perfringens enterotoxin
  • CNO
  • doxycycline
  • FGF2
  • high_cell_density
  • LPA
  • miRNA
  • okadaic_acid
  • serum
  • serum_starvation
  • stiff ECM substrate
  • U73122
  • virus infection
  • XMU-MP-1
  • Y27632
  • Zn(2+)
LATS1 (human) EHAFyEFtFRRFFDD T1079-p
LATS1 (mouse) EHAFYEFtFRRFFDD T1078-p
LATS1 (rat) EHAFYEFtFRRFFDD T1079-p
S1107-p
EYINSQGsEQQsDED
0 1
LATS1 (human) EYINSQGsEQQsDED S1107-p
LATS1 (mouse) EYIHSQGSEQQsDED S1106
LATS1 (rat) EYVSSQGSEQQSDED S1107
S1111-p
SQGsEQQsDEDDQNT
0 3
LATS1 (human) SQGsEQQsDEDDQNT S1111-p
LATS1 (mouse) SQGSEQQsDEDDQHT S1110-p
LATS1 (rat) SQGSEQQSDEDDQHT S1111